These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25207875)

  • 1. Isotretinoin exposure and risk of inflammatory bowel disease.
    Rashtak S; Khaleghi S; Pittelkow MR; Larson JJ; Lahr BD; Murray JA
    JAMA Dermatol; 2014 Dec; 150(12):1322-6. PubMed ID: 25207875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin.
    Wright S; Strunk A; Garg A
    J Am Acad Dermatol; 2021 Jan; 84(1):41-45. PubMed ID: 32682881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential association between the oral tetracycline class of antimicrobials used to treat acne and inflammatory bowel disease.
    Margolis DJ; Fanelli M; Hoffstad O; Lewis JD
    Am J Gastroenterol; 2010 Dec; 105(12):2610-6. PubMed ID: 20700115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does exposure to isotretinoin increase the risk for the development of inflammatory bowel disease? A meta-analysis.
    Lee SY; Jamal MM; Nguyen ET; Bechtold ML; Nguyen DL
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):210-6. PubMed ID: 26545085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A propensity score matched cohort study identifying an association of acne, but not oral antibiotic or isotretinoin use, with risk of incident inflammatory bowel disease.
    Taylor MT; Margolis DJ; Kwatra SG; Barbieri JS
    J Am Acad Dermatol; 2023 Apr; 88(4):841-847. PubMed ID: 36682724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of oral antibiotics before isotretinoin therapy in patients with acne.
    Nagler AR; Milam EC; Orlow SJ
    J Am Acad Dermatol; 2016 Feb; 74(2):273-9. PubMed ID: 26525749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
    Stobaugh DJ; Deepak P; Ehrenpreis ED
    J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.
    Blasiak RC; Stamey CR; Burkhart CN; Lugo-Somolinos A; Morrell DS
    JAMA Dermatol; 2013 Dec; 149(12):1392-8. PubMed ID: 24173086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isotretinoin use and the risk of inflammatory bowel disease: a population-based cohort study.
    Alhusayen RO; Juurlink DN; Mamdani MM; Morrow RL; Shear NH; Dormuth CR;
    J Invest Dermatol; 2013 Apr; 133(4):907-12. PubMed ID: 23096714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isotretinoin updates.
    On SC; Zeichner J
    Dermatol Ther; 2013; 26(5):377-89. PubMed ID: 24099068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study.
    Bernstein CN; Nugent Z; Longobardi T; Blanchard JF
    Am J Gastroenterol; 2009 Nov; 104(11):2774-8. PubMed ID: 19623167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular adverse effects of systemic treatment with isotretinoin.
    Neudorfer M; Goldshtein I; Shamai-Lubovitz O; Chodick G; Dadon Y; Shalev V
    Arch Dermatol; 2012 Jul; 148(7):803-8. PubMed ID: 22508771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relapse of acne following isotretinoin treatment: a retrospective study of 405 patients.
    Liu A; Yang DJ; Gerhardstein PC; Hsu S
    J Drugs Dermatol; 2008 Oct; 7(10):963-6. PubMed ID: 19112761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isotretinoin use and the risk of inflammatory bowel disease: a case-control study.
    Crockett SD; Porter CQ; Martin CF; Sandler RS; Kappelman MD
    Am J Gastroenterol; 2010 Sep; 105(9):1986-93. PubMed ID: 20354506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isotretinoin Exposure and Risk of Celiac Disease.
    Rashtak S; Khaleghi S; Marietta EV; Pittelkow MR; Larson JJ; Lahr BD; Murray JA
    PLoS One; 2015; 10(8):e0135881. PubMed ID: 26287738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isotretinoin and risk for inflammatory bowel disease: a nested case-control study and meta-analysis of published and unpublished data.
    Etminan M; Bird ST; Delaney JA; Bressler B; Brophy JM
    JAMA Dermatol; 2013 Feb; 149(2):216-20. PubMed ID: 23426479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and microbiological comparisons of isotretinoin vs. tetracycline in acne vulgaris.
    Oprica C; Emtestam L; Hagströmer L; Nord CE
    Acta Derm Venereol; 2007; 87(3):246-54. PubMed ID: 17533492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toward improved understanding of a potential association between isotretinoin and inflammatory bowel disease.
    Femia AN; Ann Vleugels R
    J Invest Dermatol; 2013 Apr; 133(4):866-8. PubMed ID: 23486427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isotretinoin: update on controversial issues.
    Prevost N; English JC
    J Pediatr Adolesc Gynecol; 2013 Oct; 26(5):290-3. PubMed ID: 24147278
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isotretinoin treatment in patients with acne vulgaris: does it impact muscle strength, fatigue, and endurance?
    Yıldızgören MT; Rifaioğlu EN; Demirkapı M; Ekiz T; Micooğulları A; Şen T; Turhanoğlu AD
    Cutis; 2015 Jul; 96(1):33-6. PubMed ID: 26244352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.